Response

Is CD103 a good surface marker for in vivo–activated effector/memory Treg cells in patients with chronic inflammation? Unknown yet

We observed that a percentage of CD103+ cells among CD4+FoxP3+ regulatory T (Treg) cells of donor DBA/2 mice was less than 10% before transplantation, and the percentage of CD103+ cells among donor-type CD4+FoxP3+ Treg cells increased to more than 55% in BALB/c recipients with chronic graft-versus-host disease (GVHD) and 70% in recipients without chronic GVHD after hematopoietic cell transplantation (HCT). We also observed that the percentage of CD103+ cells among FoxP3+CD4+ Treg cells in donor C57BL/6 mice was approximately 20% (mean ± SE: 20.7 ± 1.7%, N = 4) before HCT, and the percentage of CD103+ Treg cells increased to around 40% (mean ± SE: 44.3 ± 2.0%, N = 4) in BALB/c recipients with acute GVHD. These results indicate that inflammation, especially chronic inflammation, can augment the expression of CD103 on mouse FoxP3+ Treg cells, although the percentage of CD103+ cells among FoxP3+ Treg cells can differ up to certain levels in different mouse strains or different housing environments, because the percentage of CD103+ Treg cells in our DBA/2 mice is around 10%, but the percentage of our C57BL/6 mice is around 20%; the percentage of CD103+ Treg cells in our C57BL/6 mice is approximately 20%, but the percentage in C57BL/6 mice in Hühn’s reports is approximately 30%.2

It has been well documented that the percentage of CD103+ cells among FoxP3+CD4+ Treg cells in healthy humans is low, around 5%.3-5 However, it is still unknown whether FoxP3+ Treg cells in human HCT recipients express CD103. It has been shown that the percentage of CD103+ cells among CD25+CD4+ T cells was significantly higher than that among CD25−CD4+ T cells in patients with multiple sclerosis.6 In addition, in vitro TGF-β–induced Treg cells were all CD103+.7 TGF-β secretion is usually up-regulated in patients with chronic inflammation.8 Therefore, although most of the FoxP3+ Treg cells in normal humans do not express CD103, we cannot exclude the possibility that FoxP3+ Treg cells in patients with chronic inflammation (such as chronic GVHD) will up-regulate CD103 expression. Because it has been reported that effector/memory FoxP3+ Treg cells express CCR6 in mice9 and they express CD39 in multiple sclerosis patients,10 comparison of expression of CD103, CCR6, and CD39 by FoxP3+ Treg cells in patients with chronic inflammation is required to find out which one is best for identifying the FoxP3+ Treg cells.

Defu Zeng, Dongchang Zhao, and Ryotaro Nakamura

Acknowledgments: We thank Dr. Jochen Hühn at Experimentelle Rheumatologie, Charité Universitätsmedizin Berlin for his in-depth discussion, and Dr. M. Kleineviefeld and colleagues for their comments on differential surface expression of CD103 by murine and human FoxP3+ Treg cells.

This work was supported by a grant from the National Institutes of Health (Bethesda, MD, R01 AI066808 to D. Zeng). Approval for this study was obtained from the City of Hope National Medical Center Institutional Review Board.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Defu Zeng, Department of Hematology and Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010; e-mail: dzeng@coh.org

References


Response: Is CD103 a good surface marker for in vivo–activated effector/memory Treg cells in patients with chronic inflammation? Unknown yet

Defu Zeng, Dongchang Zhao and Ryotaro Nakamura